Exelixis (EXEL) Tops Q3 EPS by 22c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. LEN

Go back to Exelixis (EXEL) Tops Q3 EPS by 22c

Exelixis Announces Third Quarter 2018 Financial Results and Provides Corporate Update

November 1, 2018 4:05 PM EDT

- Total Revenues of $225.4 million -

- Cabozantinib Franchise Net Product Revenues of $162.9 million -

- Net Income of $126.6 million, Diluted EPS of $0.41 -

- Conference Call and Webcast Today at 5:00 P.M. Eastern Daylight Time -

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.... More